ONX-1006 is engineered for biocompatibility and biodegradability and designed to concentrate the chemotherapy drug (PTX) in tumors while protecting normal cells from PTX exposure. In repeated preclinical tests, much higher PTX equivalent doses were administered with no side effects.

Onselex has built a broad intellectual property portfolio covering its nanoparticle platform and potential applications.